Translating genetic findings into novel therapeutics for opioid use disorder

Active Project Grant Awarded Last action

Award ID
F31DA067203
Recipient
Awarding agency
Obligated
$43,565

Award facts

Assistance listing
93.279 Drug Use and Addiction Research Programs
Completion date 0% complete
Place of performance
La Jolla, CA 92093, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Opioid use disorder (OUD) remains a major public health crisis, with limited pharmacological treatments and high rates of relapse. Large-scale genome wide association studies (gwas) have identified dozens of genetic loci associated with opioid-related behaviors, including variants in the MU-opioid receptor OPRM1 gene. Translating these discoveries into actionable therapeutic leads for OUD is a critical next step. A central premise of this project is that a clearer understanding of the biological mechanisms underlying OUD will enable the discovery of more precise and clinically meaningful therapeutic targets. To address this goal, this proposal applies a systemic, multi-layer framework that combines large-scale opioid-related gwas with multi-omic data to identify effector genes and compounds capable of modulating OUD-relevant pathways. Aim 1 uses gwas across multiple opioid-related traits, i will quantify shared and trait-specific components of genetic liability and produce a refined set of variants. Aim 2 nominates a list of high-confidence effector genes using using fine- mapping, functional annotation, expression-based prediction models, and network-based analyses. Aim 3 integrates drug-gene evidence with AI-based evaluations of compound effects across gene networks to generate composite scores that nominate compounds with high therapeutic potential and safety profiles. The training plan builds complementary expertise in addiction neuroscience, statistical genetics, multi-omic integration, network biology, and computational pharmacology through a combination of coursework, workshops, and structured mentoring. Ucsd offers an ideal environment for this training, with unparalleled access to large-scale genomic datasets, high-performance computing resources, and a collaborative community spanning psychiatry, pharmacology, neuroscience, and quantitative genomics. Completion of this fellowship will provide rigorous training in technical and conceptual skills needed to advance translational genomic studies and generate therapeutic hypotheses and resources that can accelerate the development of urgently needed treatments for OUD.

Quick answers

Who received award F31DA067203?

F31DA067203 was awarded to University Of California, San Diego by National Institute on Drug Abuse (National Institutes of Health) on February 9, 2027.

How much is award F31DA067203 worth?

$43,565 has been obligated on F31DA067203.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login